Market Closed -
OTC Markets
13:26:13 2024-05-13 EDT
5-day change
1st Jan Change
0.0001
USD
0.00%
0.00%
+9,900.00%
Regenicin Inc. Announces Demise of Joseph Rubinfeld, Member of Board of Directors
January 03, 2017 at 01:37 pm
On December 26, 2016 Regenicin, Inc. announced that Joseph Rubinfeld, a member of board of directors passed away un-expectantly at the age of 84.
Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
23-05-15
CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022
23-02-13
CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022
23-01-13
CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022
22-08-12
CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022
22-05-23
CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021
22-02-14
CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021
22-01-13
CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021
21-08-23
CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021
21-05-17
CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020
21-01-13
CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020
20-08-19
CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020
20-05-20
CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019
20-02-19
CI
Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019
20-01-14
CI
Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2019
19-08-19
CI
Regenicin, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2019
19-05-20
CI
Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2018
19-02-19
CI
Regenicin, Inc. Announces Resignation of Craig Eagle from the Board of Directors
17-08-08
CI
Regenicin Inc. Announces Demise of Joseph Rubinfeld, Member of Board of Directors
17-01-03
CI
Regenicin Inc. Signs Supplier Agreement with Pure Med Farma LLC to Provide Closed Herd Collagen for the Manufacturing of NovaDerm
16-11-17
CI
Regenicin Completes Pre-IND Meeting with Food and Drug Administration for its New Autologous Cultured Skin Substitute, NovaDerm
16-11-01
CI
U.S. Food and Drug Administration Grants Orphan-Drug Designation for Regenicin's NovaDerm® Cultured Skin Substitute
16-08-29
CI
Regenicin, Inc. Auditor Raises 'Going Concern' Doubt
16-01-12
CI
Regenicin, Inc. announced that it has received $0.075 million in funding
13-12-30
CI
Regenicin, Inc. announced that it has received $0.025 million in funding
13-05-30
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.
More about the company
1st Jan change
Capi.
+9,900.00% 15.35K +7.52% 111B +11.38% 106B -12.64% 22.24B +0.44% 21.25B -4.18% 18.97B -37.85% 18.52B -8.58% 16.81B +37.41% 12.54B -23.95% 8.09B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
REGENICIN, INC. 